IDEAYA Biosciences, Inc.
IDYAHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeIDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. With a market capitalization of $3.75B, it sits in mid-cap territory. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Market Cap
$3.75B
Beta
-0.08
P/E (TTM)
—
P/E (Fwd)
-9.45
EPS (TTM)
$-1.92
EPS (Fwd)
$-4.11
ROE
-16.2%
ROA
-11.5%
Cash
$829.0M
Total Debt
$29.3M
Free CF
-$70.8M
52W Change
61.3%
Annual Financials
Cash vs Debt
Where IDYA stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, IDYA finished 26.16% above its 150-day moving average ($33.11) and 24.72% above its 200-day moving average ($33.49). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IDYA overbought or oversold?
At the August 28, 2026 close, IDYA's RSI(14) was 78.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $829.0M in cash and $29.3M in debt, IDYA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$70.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -16.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $50.9M to $218.7M.
With a beta below 0.7, IDEAYA Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence IDEAYA Biosciences, Inc.'s trajectory.